Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.
Read original at benzingaStocks · News reference
8-K filing — ProMIS Neurosciences Inc. (PMN)
Filed: 2026-07-28 AccNo: 0001104659-26-087269 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 28, 2026, 10:05 AM
- Checked
- Jul 28, 2026, 10:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzinga8-K filing — ProMIS Neurosciences Inc. (PMN)
Filed: 2026-08-13 AccNo: 0001104659-26-095905 Size: 246 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share
Read original at benzinga